EU Nations Considering Starting Talks With Producers of Russia's Sputnik V, Reports Suggest

© AP Photo / Zoltan BaloghA vial containing Russian vaccine Sputnik V is shown by a nurse at the South Pest Central Hospital in Budapest, Hungary, Friday, Feb. 12, 2021, as the vaccination with Sputnik V against the new coronavirus begins in the country.
A vial containing Russian vaccine Sputnik V is shown by a nurse at the South Pest Central Hospital in Budapest, Hungary, Friday, Feb. 12, 2021, as the vaccination with Sputnik V against the new coronavirus begins in the country. - Sputnik International, 1920, 15.03.2021
Subscribe
US
India
Global
MOSCOW (Sputnik) - Some European countries are considering starting talks with the creators of Russia's Sputnik V coronavirus vaccine, an EU official in charge of negotiations with the vaccine's developers told Reuters.

Four EU nations are eager to start talks, the source specified. To date, the Russian vaccine has been approved for emergency use in 50 countries

In February, Hungary became the first EU country to approve the world's first vaccine against coronavirus. Slovakia, Serbia, Montenegro, San Marino, and North Macedonia followed suit.

Earlier this month, the Russian Direct Investment Fund (RDIF), which is promoting Sputnik V in foreign markets, announced it would be able to supply the coronavirus vaccine to 50 million EU residents starting from June after the European Medicines Agency (EMA) gives it a green light.

The EMA is currently conducting a rolling review of Sputnik V.

Empty vials of the second dose of the Sputnik V (Gam-COVID-Vac) vaccine are pictured at the San Martin hospital, in La Plata, on the outskirts of Buenos Aires, Argentina January 21, 2021. - Sputnik International, 1920, 13.03.2021
Russia's Sputnik V COVID-19 Vaccine Equally Effective for All Age Groups, Developer Says
On 11 August 2020, Russia became the first country in the world to register a vaccine against the coronavirus, dubbed Sputnik V, and developed by the Gamaleya research institute with financial support from the Russian Direct Investment Fund (RDIF). 

According to the analysis of phase 3 clinical trials of Sputnik V published in The Lancet, Sputnik V has a 91.6-percent efficacy rate against symptomatic COVID-19.

Newsfeed
0
To participate in the discussion
log in or register
loader
Chats
Заголовок открываемого материала